These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 37771063)
21. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria. Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870 [TBL] [Abstract][Full Text] [Related]
22. Comparison of the Patients with Chronic Urticaria Who Responded and Did Not Respond to Omalizumab Treatment: A Single-Center Retrospective Study. Cakmak ME Int Arch Allergy Immunol; 2022; 183(11):1209-1215. PubMed ID: 36007494 [TBL] [Abstract][Full Text] [Related]
23. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders? Asero R Eur Ann Allergy Clin Immunol; 2021 Jan; 53(1):47-48. PubMed ID: 32378398 [No Abstract] [Full Text] [Related]
24. Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria? Thiede RM; Fazel M; MacDonald KM; Abraham I Expert Opin Pharmacother; 2022 Oct; 23(14):1563-1567. PubMed ID: 36173375 [No Abstract] [Full Text] [Related]
25. The Crucial Role of IgE as a Predictor of Treatment Response to Omalizumab in Chronic Spontaneous Urticaria. Maurer M; Kolkhir P; Moñino-Romero S; Metz M J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2390-2391. PubMed ID: 37364668 [No Abstract] [Full Text] [Related]
26. Predictors of treatment response in chronic spontaneous urticaria. Fok JS; Kolkhir P; Church MK; Maurer M Allergy; 2021 Oct; 76(10):2965-2981. PubMed ID: 33539587 [TBL] [Abstract][Full Text] [Related]
27. Omalizumab re-treatment rates in chronic spontaneous urticaria. Khan S; Sholtysek S Eur Ann Allergy Clin Immunol; 2020 May; 52(4):187-189. PubMed ID: 32378397 [No Abstract] [Full Text] [Related]
28. Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria. Palacios T; Stillman L; Borish L; Lawrence M J Allergy Clin Immunol Pract; 2016; 4(3):529-30. PubMed ID: 26725153 [No Abstract] [Full Text] [Related]
29. H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab. Ensina LF; Arruda LK; Campos RA; Criado RF; Rodrigues Valle S; Melo JM; Oliveira JC; Dortas JS; Cusato-Ensina AP; Camelo-Nunes IC; Agondi RC J Investig Allergol Clin Immunol; 2020 Apr; 30(2):145-147. PubMed ID: 31762438 [No Abstract] [Full Text] [Related]
30. Characteristics of patients with chronic spontaneous urticaria showing early and complete responses to omalizumab. Cho YT; Fu KT; Yang CW; Chu CY Ann Allergy Asthma Immunol; 2021 Sep; 127(3):394-395. PubMed ID: 34102302 [No Abstract] [Full Text] [Related]
31. Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria: a single-center experience. Akdaş E; Adışen E; Öztaş MO; Aksakal AB; İlter N; Gülekon A An Bras Dermatol; 2023; 98(2):240-242. PubMed ID: 36567165 [No Abstract] [Full Text] [Related]
32. A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab. Russo F; Cortonesi G; Lazzeri L; Taddeucci P; Rubegni P Dermatol Ther; 2022 Nov; 35(11):e15859. PubMed ID: 36164841 [No Abstract] [Full Text] [Related]
33. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria. Brás R; Esteves Caldeira L; Bernardino A; Costa C Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083 [TBL] [Abstract][Full Text] [Related]
34. Anti-IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series. Bonnekoh H; Kiefer L; Buttgereit T; Kolkhir P; Lütke-Eversloh M; Scheffel J; Maurer M; Metz M J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2578-2580.e1. PubMed ID: 37244440 [No Abstract] [Full Text] [Related]
36. Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis. Karstarli Bakay OS; Kacar N Dermatol Ther; 2022 Sep; 35(9):e15638. PubMed ID: 35703106 [No Abstract] [Full Text] [Related]
37. Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria. Pedersen NH; Sørensen JA; Ghazanfar MN; Zhang DG; Vestergaard C; Thomsen SF Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511088 [TBL] [Abstract][Full Text] [Related]
38. Omalizumab may not inhibit mast cell and basophil activation in vitro. Gericke J; Ohanyan T; Church MK; Maurer M; Metz M J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1832-6. PubMed ID: 25257818 [TBL] [Abstract][Full Text] [Related]
39. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria. Magen E; Waitman DA; Kahan NR Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397 [No Abstract] [Full Text] [Related]
40. Validation of UAS7 among children with chronic spontaneous urticaria. Gabrielli S; Mulé P; Prosty C; Gooding G; Le M; Zhang L; Netchiporouk E; Baum S; Greenberger S; Ensina LF; Lovett A; Zhang X; Ben-Shoshan M J Allergy Clin Immunol Pract; 2022 Jul; 10(7):1927-1929.e1. PubMed ID: 35272072 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]